Latest news with #MYOBLOC
Globe and Mail
09-04-2025
- Health
- Globe and Mail
Cerebral Palsy Market to Expand Significantly With a 3% CAGR Through 2034
Key Cerebral Palsy companies in the market include - Ipsen, Allergan (AbbVie), Supernus Pharmaceuticals, and Rohto Pharmaceutical, are at the forefront of innovation in this field. The Cerebral Palsy market has demonstrated substantial growth in recent years, driven by increasing awareness, improved diagnostic techniques, and the introduction of innovative therapies such as stem cell therapy, robot-assisted therapy, and constraint-induced movement therapy. Key pharmaceutical companies, including Ipsen, Allergan (AbbVie), Supernus Pharmaceuticals, and Rohto Pharmaceutical, are at the forefront of innovation in this field. DelveInsight's report, " Cerebral Palsy Market Insights, Epidemiology, and Market Forecast – 2034", provides a comprehensive analysis of the historical and projected market size for cerebral palsy from 2020 to 2034. The report examines various epidemiological segments and forecasts, explores market trends, assesses the competitive landscape, evaluates current and emerging therapeutic approaches, and identifies unmet needs in the treatment of cerebral palsy. According to the report, the cerebral palsy market across 7MM will experience significant growth during the forecast period, with a CAGR of around 3%. This growth will be supported by the introduction of innovative therapies in the pipeline, such as MYOBLOC, UDI-001, and other treatments, coupled with advancements in genetic testing and diagnostic techniques. Download the cerebral palsy market report to understand which factors are driving the cerebral palsy therapeutic market @ Cerebral Palsy Market Trends The report offers a thorough epidemiological analysis and forecasts extending to 2034, segmented by total cerebral palsy prevalent cases, total diagnosed cases, and total type-specific cases within the 7MM. DelveInsight estimates approximately 2 million prevalent and 2 million diagnosed cases of cerebral palsy in these regions in 2023, with numbers anticipated to rise in the coming years. The US accounts for the largest share of diagnosed cases, representing about 53% of total prevalent cases in the 7MM. Among the EU4 countries and the UK, the UK reported the highest number of cases, followed by Germany, while Italy recorded the lowest. It was also noted that spastic cerebral palsy is the most common form, affecting 70–80% of cases, followed by dyskinetic (15%) and ataxic (4%) types. These trends highlight the growing public health impact of cerebral palsy and the regional variations in disease burden. The DelveInsight report also discusses current diagnosis and treatment strategies for cerebral palsy, which are multifaceted and reflect the complexity and variability of the condition. The diagnosis of cerebral palsy typically occurs within the first two years of life through developmental monitoring, imaging tests, and evaluations of motor skills and neurological function. Treatment is highly individualized, focusing on improving motor function and quality of life. Common approaches include physical, occupational, and speech therapies to enhance mobility, daily functioning, and communication. Medications such as DYSPORT (Ipsen) and BOTOX (AbbVie), among others, are used for symptom management. In severe cases, surgical interventions may be performed to improve mobility or reduce muscle stiffness. Despite significant advancements, existing treatment approaches face various challenges, including delayed diagnosis, a lack of evidence-based guidelines, and poorly managed transitions from pediatric to adult care. Addressing these challenges requires improved diagnostic tools, better access to multidisciplinary care, enhanced communication among stakeholders, and policies that ensure equitable healthcare services for cerebral palsy patients throughout their lifespan. Discover evolving trends in the cerebral palsy treatment landscape @ Cerebral Palsy Therapeutics Market DelveInsight's analysis indicates that the current developmental pipeline for cerebral palsy treatments is highly active, with several companies initiating clinical trials for new options. Notable pipeline candidates include MYOBLOC (Supernus Pharmaceuticals), currently undergoing Phase II/III clinical trials for symptoms related to cerebral palsy in both adults and pediatric populations, and UDI-001 (Rohto Pharmaceutical) that utilizes umbilical cord-derived mesenchymal stromal cells aimed at treating cerebral palsy associated with periventricular leukomalacia, among others. The cerebral palsy treatment landscape is witnessing significant advancements in medical technology, therapeutic interventions, diagnostic tools, and funding initiatives. Recent developments have shown promising results across various fronts, offering new hope to patients, health professionals, and researchers alike. In January 2025, United Cerebral Palsy launched its 2025 "Change is Possible for CP" grant cycle to promote clinical and translational research. This program provides funding opportunities through multiple grant categories, assisting researchers and clinicians focusing on the early diagnosis and treatment of cerebral palsy. Advancements in artificial intelligence are transforming research on cerebral palsy, with numerous groundbreaking studies showcasing significant progress, particularly in early detection and neuroimaging analysis. A study conducted in February 2025 introduced an AI-powered pipeline that uses automated machine learning to assess the risk of cerebral palsy by analyzing infant movements in videos. This approach achieved an ROC-AUC score of 0.78 for predicting clinical scores at 3 to 4 months of age. Another study published in March 2025 featured a deep learning system designed to automatically quantify lesion-free brain volumes from MRI scans in children with unilateral cerebral palsy. This system successfully correlated the preservation of the thalamus with motor and visual outcomes by accurately segmenting areas of damaged brain tissue. Unlock which cerebral palsy drug is expected to capture the largest market share in 7MM by 2032. Visit the Cerebral Palsy Market Insights In conclusion, the cerebral palsy market is expected to experience substantial growth over the next decade, driven by innovative therapies, improved diagnostic techniques, and an active clinical development pipeline. According to the cerebral palsy market report by DelveInsight, the prevalence of cerebral palsy and the adoption of new treatments are projected to steadily increase across key markets. Robust advancements in medical technology and early detection methods are further enhancing the market's potential and improving patient outcomes. Table of Contents 1 Key Insights 2 Report Introduction 3 Market Overview at a Glance 4 Cerebral Palsy Epidemiology and Market Methodology 5 Cerebral Palsy Executive Summary 6 Key Events 7 Cerebral Palsy Background and Overview 8 Cerebral Palsy Diagnosis 9 Cerebral Palsy Diagnostic Guidelines 10 Cerebral Palsy Current Treatment Practices 11 Cerebral Palsy Treatment and Management Guidelines 12 Cerebral Palsy Patient Journey 13 Cerebral Palsy Epidemiology and Patient Population 14 Key Endpoints in Cerebral Palsy Clinical Trials 15 Cerebral Palsy Marketed Drugs 16 Cerebral Palsy Emerging Drugs 17 Cerebral Palsy: Market Analysis 18 Key Opinion Leaders' Views 19 SWOT 20 Cerebral Palsy Unmet Needs 21 Market Access and Reimbursement 22 Appendix 23 DelveInsight Capabilities 24 Disclaimer 25 About DelveInsight Related Reports Spastic Cerebral Palsy Pipeline Insight Spastic Cerebral Palsy Pipeline Insight provides comprehensive insights about the Spastic Cerebral Palsy pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Spastic Cerebral Palsy companies, including Ipsen, Allergan (AbbVie), Supernus Pharmaceuticals, and Rohto Pharmaceutical,, among others. About DelveInsight DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Arpit Anand Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
03-04-2025
- Health
- Globe and Mail
Cerebral Palsy Market Growth Projections 2024-2034: DelveInsight Analysis
The Key Cerebral Palsy Companies in the market include - Ipsen, Abbvie (Allergan), Supernus Pharmaceuticals, Neurocrine Biosciences, Teva Pharmaceuticals, Bundang CHA Hospital, Jazz Pharmaceuticals, Stanford University, Teva Branded Pharmaceutical, Merz Pharmaceuticals GmbH, Rohto Pharmaceutical Co., Ltd., Shionogi, and others. DelveInsight's 'Cerebral Palsy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Cerebral Palsy, historical and forecasted epidemiology as well as the Cerebral Palsy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. Some of the key facts of the Cerebral Palsy Market Report: The Cerebral Palsy market size is anticipated to grow with a significant CAGR during the study period (2020-2034) In March 2025, GeneDx (Nasdaq: WGS), a leading provider of genomic insights for better health outcomes, has announced the expansion of its genetic testing services to include cerebral palsy (CP). Timed with Cerebral Palsy Awareness Month, this initiative broadens the company's focus on pediatric rare diseases by offering testing for children with CP. The expansion highlights the importance of enhancing access to exome and genome testing, aiming to reduce diagnostic delays and expedite treatment pathways for CP patients. The cerebral palsy market is projected to experience steady growth, with a strong compound annual growth rate (CAGR) expected from 2024 to 2034. This growth across the 7MM is fueled by the launch of new therapies like MYOBLOC and UDI-001, as well as improvements in genetic testing and diagnostic methods. According to DelveInsight's epidemiology model, there were roughly 1.9 million prevalent cases of cerebral palsy in the 7MM in 2023, including about 1.8 million diagnosed cases. This figure is expected to increase during the study period from 2020 to 2034. In 2023, the US reported the largest number of diagnosed cerebral palsy cases within the 7MM, totaling nearly 932 thousand, which accounts for about 53% of all cases in these areas. In 2023, the UK recorded the highest number of diagnosed cerebral palsy cases among the EU4 and the UK, with about 142 thousand cases, followed closely by Germany with nearly 134 thousand cases. In contrast, Italy had the fewest diagnosed cases, totaling around 105 thousand. In 2023, Japan recorded around 221 thousand cases of cerebral palsy, and this figure is projected to change by 2034. In 2023, the breakdown of type-specific cerebral palsy cases in the US included about 755 thousand spastic cases, 26 thousand dyskinetic cases, 24 thousand ataxic cases, 26 thousand hypotonic cases, and nearly 151 thousand cases classified as other or mixed types. These figures are expected to increase over the study period. Key Cerebral Palsy Companies: Ipsen, Abbvie (Allergan), Supernus Pharmaceuticals, Neurocrine Biosciences, Teva Pharmaceuticals, Bundang CHA Hospital, Jazz Pharmaceuticals, Stanford University, Teva Branded Pharmaceutical, Merz Pharmaceuticals GmbH, Rohto Pharmaceutical Co., Ltd., Shionogi, and others Key Cerebral Palsy Therapies: DYSPORT (abobotulinumtoxin A), Botox (Onabotulinum toxin A), MYOBLOC (RimabotulinumtoxinB), VALBENAZINE, AUSTEDO, Erythropoietin, Sativex, Botulinum Toxin type B, TEV-50717, IncobotulinumtoxinA, UDI-001, Oral Glycopyrrolate Liquid, and others The Cerebral Palsy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cerebral Palsy pipeline products will significantly revolutionize the Cerebral Palsy market dynamics. Cerebral Palsy Overview Cerebral Palsy comprises a collection of conditions impacting movement, muscle tone, and posture. The condition arises from damage to the developing brain, typically occurring before birth, which can affect motor function control. Those affected may experience challenges with both voluntary and involuntary movements, leading to unsteady or lax motions. Get a Free sample for the Cerebral Palsy Market Forecast, Size & Share Analysis Report: Cerebral Palsy Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Cerebral Palsy Epidemiology Segmentation: The Cerebral Palsy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Download the report to understand which factors are driving Cerebral Palsy epidemiology trends @ Cerebral Palsy Epidemiology Forecast Cerebral Palsy Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cerebral Palsy market or expected to get launched during the study period. The analysis covers Cerebral Palsy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Cerebral Palsy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Cerebral Palsy Therapies and Key Companies Discover more about therapies set to grab major Cerebral Palsy market share @ Cerebral Palsy Treatment Landscape Cerebral Palsy Market Strengths Stem cell therapy is a novel treatment for Cerebral Palsy compared with symptomatic standard care has shown a significant positive effect on gross motor function. Short term safety is present, and further investigations are ongoing. Cerebral Palsy Market Opportunities Due to increasingly compelling evidence that Cerebral Palsy can have a genetic component, studies are testing interventions such as deep brain stimulation (DBS) and personalized medicine for the treatment of patients with Cerebral Palsy. Scope of the Cerebral Palsy Market Report Study Period: 2020–2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Cerebral Palsy Companies: Ipsen, Abbvie (Allergan), Supernus Pharmaceuticals, Neurocrine Biosciences, Teva Pharmaceuticals, Bundang CHA Hospital, Jazz Pharmaceuticals, Stanford University, Teva Branded Pharmaceutical, Merz Pharmaceuticals GmbH, Rohto Pharmaceutical Co., Ltd., Shionogi, and others Key Cerebral Palsy Therapies: DYSPORT (abobotulinumtoxin A), Botox (Onabotulinum toxin A), MYOBLOC (RimabotulinumtoxinB), VALBENAZINE, AUSTEDO, Erythropoietin, Sativex, Botulinum Toxin type B, TEV-50717, IncobotulinumtoxinA, UDI-001, Oral Glycopyrrolate Liquid, and others Cerebral Palsy Therapeutic Assessment: Cerebral Palsy current marketed and Cerebral Palsy emerging therapies Cerebral Palsy Market Dynamics: Cerebral Palsy market drivers and Cerebral Palsy market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Cerebral Palsy Unmet Needs, KOL's views, Analyst's views, Cerebral Palsy Market Access and Reimbursement Table of Contents 1. Cerebral Palsy Market Report Introduction 2. Executive Summary for Cerebral Palsy 3. SWOT analysis of Cerebral Palsy 4. Cerebral Palsy Patient Share (%) Overview at a Glance 5. Cerebral Palsy Market Overview at a Glance 6. Cerebral Palsy Disease Background and Overview 7. Cerebral Palsy Epidemiology and Patient Population 8. Country-Specific Patient Population of Cerebral Palsy 9. Cerebral Palsy Current Treatment and Medical Practices 10. Cerebral Palsy Unmet Needs 11. Cerebral Palsy Emerging Therapies 12. Cerebral Palsy Market Outlook 13. Country-Wise Cerebral Palsy Market Analysis (2020–2034) 14. Cerebral Palsy Market Access and Reimbursement of Therapies 15. Cerebral Palsy Market Drivers 16. Cerebral Palsy Market Barriers 17. Cerebral Palsy Appendix 18. Cerebral Palsy Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
